The DSTN Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DSTN gene, which encodes actin depolymerizing factor (ADF). This loss-of-function model enables investigation of ADF’s role in actin filament dynamics. As a polyclonal population, it facilitates bulk functional studies while maintaining biological variability.
The host HeLa cell line is an immortalized human cervical adenocarcinoma cell line, originally derived from an HPV18-positive tumor. HeLa cells exhibit an adherent epithelial morphology and are widely used in cancer biology due to their transformed phenotype and the presence of HPV oncogenes, which influence cell cycle and motility.
DSTN binds both G-actin and F-actin, promoting filament severing and depolymerization to regulate actin turnover. Its activity is controlled by upstream regulators including RhoA, Rac1, Cdc42, LIMK1, and SSH1, with LIMK-mediated phosphorylation inhibiting DSTN and SSH1-mediated dephosphorylation reactivating it. Within the Rho GTPase pathway, RhoA activates ROCK and LIMK to phosphorylate cofilin/ADF family members, while Rac1 and Cdc42 can signal through SSH to relieve inhibition. DSTN interacts directly with actin and functions in concert with cofilin and profilin to modulate F-actin disassembly and G-actin availability.
In HeLa cells, DSTN knockout perturbs actin-dependent processes essential for cell migration, invasion, and cytokinesis??hallmarks of metastatic cancer. The HPV18-positive background, characterized by E6/E7 oncoprotein expression, may synergistically alter cytoskeletal regulation, making this knockout model valuable for studying actin dynamics in a tumorigenic context and for identifying therapeutic vulnerabilities.
This polyclonal knockout cell population is suited for actin polymerization assays, fluorescence microscopy of the actin cytoskeleton, wound healing and Transwell migration/invasion assays, and Western blotting for phospho-DSTN or co-immunoprecipitation with actin. It also facilitates signal transduction studies exploring RhoA- and Rac1-mediated cytoskeletal control and can be used in drug testing for compounds targeting actin dynamics. For further information, please contact Ascent Research.
